Original articleGeneral thoracicResults of Neoadjuvant Chemoradiotherapy With Docetaxel and 5-Fluorouracil Followed by Esophagectomy to Treat Locally Advanced Esophageal Cancer
Section snippets
Patient Characteristics
We reviewed data from 38 patients (male, n = 34; female, n = 4; mean age, 61.3 ± 9.2 years; range, 42 to 78 years) who received neoadjuvant CRT with DOC and 5FU followed by esophagectomy between September 2003 and January 2008 (Table 1). This was the preferred neoadjuvant CRT regimen for treating resectable advanced esophageal cancer in our institute at the time. The present retrospective review of a prospective database was approved by the Institutional Review Board at Hiroshima University.
Clinical Effect and Toxicity of Neoadjuvant Chemoradiotherapy
All patients completed the neoadjuvant CRT regimen. The clinical outcomes of neoadjuvant CRT comprised a complete response (CR) in 2 (5.3%) patients, a partial response in 29 (76.3%), stable disease in 6 (15.8%), and progressive disease in 1 (2.6%). Therefore, the overall clinical response rate was 81.6%. One patient with progressive disease developed lymph node metastasis outside the irradiation field after neoadjuvant CRT.
Table 2 shows the toxicity of neoadjuvant CRT. Hematologic toxicity was
Comment
We previously reported a phase I study of setting the doses of DOC and 5FU for definitive CRT to treat advanced esophageal cancer [13], and plan to publish the results of a phase II study of this definitive CRT. Moreover, we found high antitumor activity in a phase II study of combination chemotherapy with DOC and the oral fluorouracil antitumor drug S-1 for treating advanced or recurrent gastric cancer [23]. We applied neoadjuvant CRT to patients with esophageal cancer based on these
References (30)
- et al.
Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal carcinoma: an updated meta-analysis
Lancet Oncol
(2011) - et al.
Trimodality therapy for stage II-III carcinoma of the esophagus: a dose-ranging study of concurrent capecitabine, docetaxel, and thoracic radiotherapy
J Thorac Oncol
(2013) - et al.
Docetaxel administration schedule: from fever to tears? A review of randomised studies
Eur J Cancer
(2005) - et al.
Preoperative chemoradiotherapy for oesophageal cancer: a systematic review and meta-analysis
Gut
(2004) - et al.
Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781
J Clin Oncol
(2008) - et al.
Cisplatin: a review of toxicities and therapeutic applications
Vet Comp Oncol
(2008) Carvalho Rodrigues MA, Martins NM, dos Santos AC. Cisplatin-induced nephrotoxicity and targets of nephroprotection: an update
Arch Toxicol
(2012)- et al.
Preoperative chemoradiotherapy for esophageal or junctional cancer
N Engl J Med
(2012) - et al.
S0356: a phase II clinical and prospective molecular trial with oxaliplatin, fluorouracil, and external-beam radiation therapy before surgery for patients with esophageal adenocarcinoma
J Clin Oncol
(2011) - et al.
Trimodality therapy without a platinum compound for localized carcinoma of the esophagus and gastroesophageal junction
Cancer
(2010)
Docetaxel alone or orally combined with 5-fluorouracil and its derivatives: effects on mouse mammary tumor cell line MM2 in vitro and in vivo
Anticancer Drugs
Antitumor efficacy of sequential treatment with docetaxel and 5-fluorouracil against human oral cancer cells
Int J Oncol
Synergistic effects of docetaxel and S-1 by modulating the expression of metabolic enzymes of 5-fluorouracil in human gastric cancer cell lines
Int J Cancer
Phase I study of docetaxel (TXT) and 5-fluorouracil (5-FU) with concurrent radiotherapy in patients with advanced esophageal cancer
Anticancer Res
Cited by (31)
Prognostic value of quantitative parameters for esophageal squamous cell carcinoma determined by preoperative FDG-PET after trimodal therapy
2022, Surgery (United States)Citation Excerpt :The Institutional Review Board at Hiroshima University approved this study (approval number: E-2225). Neoadjuvant chemoradiotherapy and surgery comprised concurrent radiotherapy (40 Gy in 20 fractions) and chemotherapy with 5-fluorouracil and either docetaxel or cisplatin or a combination of both, as described.5,12,18,19 The chemotherapy regimens were docetaxel/5-fluorouracil, cisplatin/5-fluorouracil, docetaxel/cisplatin/5-fluorouracil, or nedaplatin/5-fluorouracil in 9 (7.5%), 88 (73.3%), 18 (15.0%), and 5 (4.2%) patients, respectively.
Preoperative prediction of a pathologic complete response of esophageal squamous cell carcinoma to neoadjuvant chemoradiotherapy
2018, Surgery (United States)Citation Excerpt :The Institutional Review Board at Hiroshima University approved this study. The NCRT comprised concurrent radiotherapy (40 Gy) and chemotherapy with 5-fluorouracil and either docetaxel or cisplatin or a combination of both, as described.5,8-10 The clinical responses of the primary tumors and LNs after NCRT were evaluated by CT, PET, and endoscopy at 3 to 7 weeks after NCRT.
Ability of Fluorine-18 Fluorodeoxyglucose Positron Emission Tomography to Predict Outcomes of Neoadjuvant Chemoradiotherapy Followed by Surgical Treatment for Esophageal Squamous Cell Carcinoma
2016, Annals of Thoracic SurgeryCitation Excerpt :The clinicopathologic profiles of the tumors were based on the TNM Classification of Malignant Tumors, 7th edition [13]. Neoadjuvant CRT comprised concurrent radiotherapy (40 Gy) and chemotherapy with 5-fluorouracil and either docetaxel or cisplatin, or a combination of both [5, 14, 15]. The chemotherapy regimen between 2003 and 2007 consisted of a combination of docetaxel and 5-fluorouracil [5].